Emgality (galcanezumab) 100 mg — United Healthcare

Initial criteria

• Diagnosis of episodic cluster headache
• Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months
• Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy, Nurtec ODT, Qulipta, Vyepti)

Reauthorization criteria

• Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity
• Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraine (e.g., Aimovig, Ajovy, Nurtec ODT, Qulipta, Vyepti)

Approval duration

12 months